What are the indications, dosing regimens, contraindications, and adverse effects of tranexamic acid?

Tranexamic Acid: Indications, Dosing, Contraindications, and Adverse Effects

Tranexamic acid is a life-saving antifibrinolytic agent with three primary indications: postpartum hemorrhage (within 3 hours of birth), trauma with significant hemorrhage (within 3 hours of injury), and hemophilia-related dental procedures. 1, 2

Life-Saving Indications

Postpartum Hemorrhage

• Administer 1 g IV over 10 minutes to all women with clinically diagnosed PPH (>500 mL vaginal birth, >1000 mL cesarean, or any loss compromising hemodynamic stability), regardless of cause. 1
• Timing is critical: therapeutic benefit declines approximately 10% for every 15-minute delay; no benefit after 3 hours, and administration beyond this window may be harmful. 1
• A second 1 g dose may be given if bleeding persists after 30 minutes or recurs within 24 hours. 1
• This is a WHO strong recommendation based on high-quality evidence. 1

Trauma with Significant Hemorrhage

• Indicated for trauma patients bleeding or at risk of major hemorrhage; administer as soon as possible and within 3 hours of injury. 1
• Dosing: 1 g IV loading dose over 10 minutes, followed by 1 g continuous infusion over 8 hours. 1
• The CRASH-2 trial demonstrated reduced mortality with early administration in severely injured patients. 1
• When feasible, administer en route to hospital by emergency medical services. 1
• Meta-analysis confirms significant reduction in 24-hour mortality (prehospital: log risk ratio -0.29, p=0.02; in-hospital: -0.38, p=0.02) and 30-day mortality. 3

Hemophilia-Related Dental Procedures

• FDA-approved indication: 10 mg/kg IV immediately before tooth extraction, infused no faster than 1 mL/minute to avoid hypotension. 2
• Post-extraction: 10 mg/kg IV 3-4 times daily for 2-8 days. 2

Additional Surgical Indications

Emergency and Urgent Surgery

• Reduces perioperative bleeding and transfusion requirements in emergency surgical procedures. 1
• Meta-analyses demonstrate 29-54% reductions in postoperative blood loss in cardiac surgery with cardiopulmonary bypass. 4
• Effective in orthopedic arthroplasty, prostatectomy (TURP), and liver transplantation. 5, 4, 6

Dosing Regimens

Standard Dosing

• Most common regimen: 10-15 mg/kg IV bolus (or 1 g), followed by maintenance infusion of 1 mg/kg/hour. 4
• Maximum total dose: 100 mg/kg, especially in patients over 50 years of age, to avoid neurotoxicity. 7
• Recent pharmacokinetic modeling suggests optimal plasma levels (50-75 mg/L) are maintained with 15 mg/kg bolus over 15 minutes plus 7.5 mg/kg/hour maintenance infusion for 2 hours. 8

Renal Impairment Dosing

Dose reduction is mandatory in renal dysfunction (tranexamic acid is renally cleared): 2

• Serum creatinine 1.36-2.83 mg/dL: 10 mg/kg twice daily
• Serum creatinine 2.83-5.66 mg/dL: 10 mg/kg once daily
• Serum creatinine >5.66 mg/dL: 10 mg/kg every 48 hours OR 5 mg/kg every 24 hours

For chronic kidney disease patients (eGFR <60 mL/min/1.73 m²) undergoing arthroplasty, reduce maintenance infusion to 5 mg/kg/hour. 8

Absolute Contraindications

Three absolute contraindications exist: 1, 2

1. Active intravascular clotting (ongoing thrombus formation)
2. Subarachnoid hemorrhage (risk of cerebral edema and cerebral infarction)
3. Hypersensitivity to tranexamic acid or any ingredient

Additional contraindication for PPH indication: known thromboembolic event during pregnancy. 1

Warnings and Precautions

Thromboembolic Risk

• Tranexamic acid increases risk of venous and arterial thrombosis/thromboembolism. 2
• Avoid concomitant use with prothrombotic agents: Factor IX complex concentrates, anti-inhibitor coagulant concentrates, and hormonal contraceptives. 2
• However, meta-analyses have not demonstrated increased thromboembolic events in surgical trials, and vaso-occlusive events did not differ in trauma studies. 4, 3

Seizures

• Dose-dependent risk: most common with doses exceeding 100 mg/kg, particularly in cardiovascular surgery (10-fold higher than recommended doses). 2, 9
• Risk factors include renal dysfunction and inadvertent neuraxial administration. 2
• Consider EEG monitoring in patients with seizure history or who develop myoclonic movements. 2
• Discontinue immediately if seizures occur. 2

Route of Administration Errors

• FOR INTRAVENOUS USE ONLY—serious adverse reactions including seizures and cardiac arrhythmias occur with inadvertent intrathecal administration. 2
• Syringes must be clearly labeled with IV route. 2

Hypersensitivity Reactions

• Anaphylactic reactions have occurred; discontinue immediately if severe reaction develops. 2

Visual Disturbances

• Focal retinal degeneration observed in animal studies at high doses (250-1600 mg/kg/day). 2
• Discontinue if visual or ocular symptoms occur. 2

Hypotension

• Infuse no faster than 1 mL/minute to avoid hypotension. 2

Common Adverse Effects

Most adverse events are mild to moderate: 2, 9, 10

• Nausea and diarrhea (most common)
• Vomiting
• Headache
• Dizziness/giddiness (advise patients not to drive if this occurs)
• Nasal symptoms
• Fatigue
• Allergic dermatitis

Severe events are rare in clinical trials. 10, 5

Administration Considerations

Compatibility

• May be mixed with electrolyte solutions, carbohydrate solutions, amino acid solutions, and dextran solutions. 2
• Heparin may be added. 2
• Do NOT mix with blood or penicillin-containing solutions. 2
• Diluted mixture may be stored up to 4 hours at room temperature. 2

Clinical Pitfalls

• The 3-hour window is critical for trauma and PPH—delays significantly reduce efficacy and may cause harm. 1
• Do not exceed 50 mg/kg total dose to minimize seizure risk. 9
• Always adjust dose for renal impairment—failure to do so increases adverse event risk. 2, 8
• Verify IV route before administration—intrathecal administration causes seizures. 2